CN107207441B - 蛋白激酶抑制剂 - Google Patents

蛋白激酶抑制剂 Download PDF

Info

Publication number
CN107207441B
CN107207441B CN201580071637.2A CN201580071637A CN107207441B CN 107207441 B CN107207441 B CN 107207441B CN 201580071637 A CN201580071637 A CN 201580071637A CN 107207441 B CN107207441 B CN 107207441B
Authority
CN
China
Prior art keywords
methyl
thiazolo
phenyl
pyridin
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201580071637.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN107207441A (zh
Inventor
赵兴东
丁健
蒙凌华
耿美玉
李同双
周祖文
陈岭
刘启洪
王宪龙
杨理君
容悦
谭锐
于垂亮
姜立花
刘研新
令狐莉
孙婧
王为波
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chongqing Fushang Yuanchuang Pharmaceutical Technology Co ltd
Shanghai Institute of Materia Medica of CAS
Original Assignee
Shanghai Institute of Materia Medica of CAS
Shanghai Fochon Pharmaceutical Co Ltd
Fochon Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Materia Medica of CAS, Shanghai Fochon Pharmaceutical Co Ltd, Fochon Pharmaceuticals Ltd filed Critical Shanghai Institute of Materia Medica of CAS
Publication of CN107207441A publication Critical patent/CN107207441A/zh
Application granted granted Critical
Publication of CN107207441B publication Critical patent/CN107207441B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201580071637.2A 2014-11-01 2015-11-01 蛋白激酶抑制剂 Expired - Fee Related CN107207441B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462073993P 2014-11-01 2014-11-01
US62/073,993 2014-11-01
PCT/CN2015/093551 WO2016066142A1 (en) 2014-11-01 2015-11-01 Certain protein kinase inhibitors

Publications (2)

Publication Number Publication Date
CN107207441A CN107207441A (zh) 2017-09-26
CN107207441B true CN107207441B (zh) 2020-11-24

Family

ID=55856639

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580071637.2A Expired - Fee Related CN107207441B (zh) 2014-11-01 2015-11-01 蛋白激酶抑制剂

Country Status (9)

Country Link
US (1) US10328060B2 (enExample)
EP (1) EP3224248B1 (enExample)
JP (1) JP6831324B2 (enExample)
CN (1) CN107207441B (enExample)
AU (1) AU2015341186B2 (enExample)
BR (1) BR112017008867A2 (enExample)
CA (1) CA2966252C (enExample)
ES (1) ES2879809T3 (enExample)
WO (1) WO2016066142A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1232227A1 (zh) * 2014-07-04 2018-01-05 Lupin Limited 作为pi3k抑制剂的喹嗪酮衍生物
WO2017103825A1 (en) 2015-12-18 2017-06-22 Lupin Limited Quinolizinone derivatives as pi3k inhibitors
CA3178569A1 (en) * 2020-05-16 2021-11-25 Zuwen ZHOU Compounds as protein kinase inhibitors
WO2022228387A1 (en) * 2021-04-26 2022-11-03 Fochon Biosciences, Ltd. Compounds as parp inhibitors
WO2023078401A1 (en) * 2021-11-05 2023-05-11 Fochon Biosciences, Ltd. Compounds as protein kinase inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101605797A (zh) * 2006-11-13 2009-12-16 伊莱利利公司 治疗炎症疾病和癌症的噻吩并嘧啶酮
CN102482278A (zh) * 2009-06-29 2012-05-30 因塞特公司 作为pi3k抑制剂的嘧啶酮类
CN103649089A (zh) * 2011-04-29 2014-03-19 阿尔米雷尔有限公司 作为pi3k抑制剂的吡咯并三嗪酮

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS545996A (en) * 1977-06-15 1979-01-17 Yamanouchi Pharmaceut Co Ltd Heterocyclic compounds and process for their preparation
AU5991699A (en) * 1998-09-21 2000-04-10 Biochem Pharma Inc. Quinolizinones as integrin inhibitors
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
WO2005113556A1 (en) 2004-05-13 2005-12-01 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
US8557830B2 (en) 2007-06-07 2013-10-15 Amgen Inc. RAF kinase modulators and methods of use
US8916593B2 (en) 2010-05-04 2014-12-23 Pfizer Inc. Alkoxy-substituted 2-aminopyridines as ALK inhibitors
DK2812004T3 (en) * 2012-02-10 2018-10-15 Ptc Therapeutics Inc COMPOUNDS FOR TREATMENT OF SPINAL MUSCLE DROPHY
WO2013149362A1 (en) 2012-04-06 2013-10-10 Glaxosmithkline Llc 1-(dihydronaphthalenyl)pyridones as melanin-concentrating hormone receptor 1 antagonists
HK1232227A1 (zh) * 2014-07-04 2018-01-05 Lupin Limited 作为pi3k抑制剂的喹嗪酮衍生物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101605797A (zh) * 2006-11-13 2009-12-16 伊莱利利公司 治疗炎症疾病和癌症的噻吩并嘧啶酮
CN102482278A (zh) * 2009-06-29 2012-05-30 因塞特公司 作为pi3k抑制剂的嘧啶酮类
CN103649089A (zh) * 2011-04-29 2014-03-19 阿尔米雷尔有限公司 作为pi3k抑制剂的吡咯并三嗪酮

Also Published As

Publication number Publication date
US10328060B2 (en) 2019-06-25
BR112017008867A2 (pt) 2017-12-26
ES2879809T3 (es) 2021-11-23
EP3224248A1 (en) 2017-10-04
US20180036293A1 (en) 2018-02-08
EP3224248A4 (en) 2018-08-08
EP3224248B1 (en) 2021-05-05
WO2016066142A1 (en) 2016-05-06
JP6831324B2 (ja) 2021-02-17
JP2017533232A (ja) 2017-11-09
AU2015341186B2 (en) 2019-11-14
AU2015341186A1 (en) 2017-06-08
CN107207441A (zh) 2017-09-26
CA2966252A1 (en) 2016-05-06
CA2966252C (en) 2023-10-24

Similar Documents

Publication Publication Date Title
CN111892579B (zh) 一类激酶抑制剂
ES2724578T3 (es) Ciertos inhibidores de proteína quinasas
CN104854101B (zh) Alk激酶抑制剂
CN110372720B (zh) 一类激酶抑制剂
WO2023016434A1 (en) Compounds targeting mutant of p53
CN107207441B (zh) 蛋白激酶抑制剂
JP2022521537A (ja) イミダゾピリジニル化合物及び増殖性障害の処置のためのその使用
JP2023551272A (ja) ジアシルグリセロールキナーゼ阻害剤としての複素環化合物及びその用途
CN111699188B (zh) [1,2,4]三唑并[4,3-a]吡嗪-8-酮衍生物
US20160145244A1 (en) Certain protein kinase inhibitors
HK1240216B (zh) 蛋白激酶抑制剂
HK1240216A1 (en) Certain protein kinase inhibitors
CA3178569A1 (en) Compounds as protein kinase inhibitors
HK1218119B (en) Certain protein kinase inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1240216

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20230414

Address after: 401121 building F, No. 2, Yangliu Road, Yubei District, Chongqing

Patentee after: Chongqing Fushang Yuanchuang Pharmaceutical Technology Co.,Ltd.

Patentee after: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Address before: Room 512, A Building, 1289 Yishan Road, Xuhui District, Shanghai, 2003

Patentee before: CHINA SHANGHAI FOCHON PHARMACEUTICAL Co.,Ltd.

Patentee before: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Patentee before: FOCHON PHARMACEUTICALS, LTD.

TR01 Transfer of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20201124

CF01 Termination of patent right due to non-payment of annual fee